Pacific Crest Upgrades Expedia (EXPE) to Overweight
Get Alerts EXPE Hot Sheet
Rating Summary:
23 Buy, 32 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Pacific Crest upgraded Expedia (NASDAQ: EXPE) from Sector Weight to Overweight with a price target of $160. Analyst Brad Erickson noted positive HomeAway checks, along with favorable risk/reward.
"Conversations with property owners indicate overall high satisfaction with the HomeAway platform, very limited desire and ability to move to competing platforms and greater confidence in passenger fee implementation and take-rate levels already being achieved. We think this is under-appreciated in shares at current levels," said Erickson.
"We are establishing EBITDA estimates by segment, enabling a sum-of-the-parts valuation. We are also making an appropriate, albeit slight, upward adjustment to our 2016 and 2017 EBITDA estimates via D&A; our EPS estimates are unchanged. Additionally, we are establishing 2018 revenue, EBITDA and EPS estimates. We are forecasting a 21% three-year revenue CAGR from 2015-2018; we expect some leverage from lower tech & content and G&A costs to drive faster EBITDA and earnings growth of 27% and 28%, respectively," continued the analyst.
Erickson concluded, "Given some mixed hotel data during the quarter, we are not making a call on the quarter; however, HomeAway checks combined with our view of Expedia having multiple levers to support growth over the next few years give us incremental confidence in the story despite the recent mini-run in the stock. We are buyers and see upside to $160 based on a sum-of-the-parts analysis with a bull case approaching $200."
For an analyst ratings summary and ratings history on Expedia click here. For more ratings news on Expedia click here.
Shares of Expedia closed at $124.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Tesla (TSLA) to Buy on wind up of positive catalysts
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
Create E-mail Alert Related Categories
Analyst Comments, Hot Comments, Hot Upgrades, UpgradesRelated Entities
Pacific Crest Securities, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!